What is the best way to take CBD for maximum absorption?

Sublingual administration (holding oil under the tongue for 60–90 seconds) achieves faster onset and higher peak concentrations than swallowing. Oral CBD taken with a high-fat meal increases bioavailability from ~6% to ~35%. Inhalation has the highest bioavailability (10–35%) but shortest duration. The best route depends on the intended use — sublingual for faster onset, oral for longer duration.

Does CBD interact with medications?

Yes — significantly. CBD inhibits CYP2C19 and CYP3A4 liver enzymes, which metabolize many common medications. Clinically important interactions include: clobazam (increased active metabolite — dose reduction needed), warfarin (increased anticoagulation — INR monitoring required), tacrolimus and cyclosporine (immunosuppressant levels increase), and many others. Always consult a pharmacist or physician before combining CBD with prescription medications.

What is the entourage effect?

The entourage effect is the hypothesis that whole-plant cannabis preparations are more therapeutically effective than isolated cannabinoids because terpenes, flavonoids, and minor cannabinoids act synergistically. There is biological plausibility — terpenes like myrcene and linalool do interact with cannabinoid receptors. However, clinical evidence is limited and methodologically weak. The entourage effect is often overstated in marketing.

How long does THC stay in your system?

THC is detectable in urine for 3–30 days depending on frequency of use — occasional users typically 3–7 days, daily users up to 30 days. In blood, THC is detectable for 1–2 days after occasional use, longer with chronic use. Hair follicle tests can detect THC for up to 90 days. CBD does not cause a positive drug test for THC, but contaminated CBD products might.

Research Topic

Cannabinoid Pharmacology

How cannabinoids work, how they're absorbed, and how they interact

Understanding cannabinoid pharmacology is essential for interpreting clinical research and making safe therapeutic decisions. Bioavailability varies dramatically by route of administration, drug interactions are clinically significant, and the pharmacokinetics of THC and CBD differ substantially.

1,800+ indexed studies Updated May 2026 Reviewed by MD + PhD Evidence Standards

What the Research Shows

Cannabinoid pharmacology is complex and often misunderstood. THC is a partial agonist at CB1 and CB2 receptors, producing psychoactive effects through CB1 activation in the CNS. CBD has a much broader pharmacological profile — it is a negative allosteric modulator of CB1, an agonist at 5-HT1A and TRPV1 receptors, and an inhibitor of adenosine reuptake, among other actions. Bioavailability varies enormously: inhaled THC achieves 10–35% bioavailability with rapid onset; oral CBD has only 6% bioavailability due to first-pass metabolism, rising to ~35% with high-fat food. Sublingual administration offers intermediate bioavailability with faster onset than oral. Drug interactions are a critical clinical concern: CBD is a potent inhibitor of CYP2C19 and CYP3A4, affecting levels of clobazam, warfarin, tacrolimus, and many other medications. THC is metabolized by CYP2C9 and CYP3A4. The entourage effect — the hypothesis that whole-plant preparations are more effective than isolated compounds — has biological plausibility but limited clinical evidence.

Key Findings

Oral CBD bioavailability is only ~6%

Well-Studied

First-pass metabolism severely limits oral CBD absorption; high-fat meals increase bioavailability to ~35%.

CBD inhibits CYP2C19 and CYP3A4

Well-Studied

Clinically significant drug interactions with clobazam, warfarin, tacrolimus, and other narrow therapeutic index drugs.

Sublingual CBD achieves 35% higher Cmax than oral

Emerging Research

Sublingual administration bypasses first-pass metabolism, achieving faster and higher peak plasma concentrations.

Entourage effect has preclinical support, limited clinical evidence

Limited Evidence

Myrcene and linalool show synergistic activity with CBD in preclinical models; clinical evidence remains heterogeneous.

Featured Studies

View all in library

Common Questions

What We Still Don't Know

These are open research questions — areas where the evidence is insufficient or actively contested.

1What is the clinical significance of the entourage effect in controlled trials?
2How do genetic polymorphisms in CYP2C9 and CYP2C19 affect cannabinoid metabolism?
3What is the optimal dosing strategy to minimize tolerance development?
4How do cannabinoid pharmacokinetics change with age, sex, and body composition?
5Can nanoformulation technology meaningfully improve oral CBD bioavailability?

Anxiety & Mental Health Pain & Inflammation Sleep Disorders Epilepsy & Seizures Cancer & Oncology Neuroscience Full Research Library

Cannabinoid Pharmacology

What the Research Shows

Key Findings

Featured Studies

CBD Bioavailability: Oral vs. Sublingual Administration Comparison

Terpene Entourage Effects: A Systematic Review of Synergistic Cannabinoid Interactions

Cannabidiol Drug Interactions: A Systematic Review of CYP450 Inhibition

Common Questions

What We Still Don't Know

Cannabinoid Pharmacology

What the Research Shows

Key Findings

Featured Studies

CBD Bioavailability: Oral vs. Sublingual Administration Comparison

Terpene Entourage Effects: A Systematic Review of Synergistic Cannabinoid Interactions

Cannabidiol Drug Interactions: A Systematic Review of CYP450 Inhibition

Common Questions

What We Still Don't Know

Related Research Topics